Video

Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

Author(s):

Andrew J. Armstrong, MD,Matthew Manning, MD

Drs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.

Related Videos
1 expert in this video
1 expert in this video
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
FDA
November 21st 2024

FDA Accepts sNDA for Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

David Parkinson, MD, president, chief executive officer, ESSA
November 1st 2024

ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC

Neeraj Agarwal, MD, FASCO, Presidential Endowed Chair of Cancer Research, Huntsman Cancer Institute; professor, medicine, University of Utah
October 31st 2024

Novel Prostate Cancer Treatment Increases Overall Survival Rates for Late-Stage Prostate Cancer Patients